Pipeline news

• Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy

  06 March 2019

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it is initiating a single global pivotal Phase 3 clinical study (Violet Study) evaluating oral ganaxolone in children with PCDH19-related epilepsy (PCDH19-RE), a rare genetic epilepsy. If successful, the Violet Study is intended to support the regulatory filings for approval of ganaxolone in this underserved and refractory patient population.

• Marinus Announces Leadership Transition

  26 February 2019

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that chief executive officer, Christopher M. Cashman, will leave the Company to pursue other opportunities in the life science industry effective March 18, 2019.  Scott Braunstein, M.D., currently a director on the Company’s Board, has been appointed executive chairman.  Marinus has retained an executive search firm to identify Mr. Cashman’s successor as CEO.

• Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019

  20 February 2019

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that it received notification from the  U.S. Food and Drug Administration  ( FDA ) that the Agency has accepted for review the New Drug Application (NDA) for XIPERE (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for the treatment of macular edema associated with uveitis. The  FDA  has determined that the application is sufficiently complete to permit a substantive review.

• Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  25 January 2019

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 105,000 shares of its common stock to five new employees, with a grant date of January 24, 2019.

• Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose

  18 January 2019

  

  Clearside Biomedical , Inc., a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from MAGNOLIA, an extension study of PEACHTREE, its pivotal Phase 3 trial of XIPERE™ (formerly “suprachoroidal CLS-TA”) in patients with macular edema associated with non-infectious uveitis, was presented by Pauline Merrill, MD during the winter symposium of the  American Uveitis Society  in Park City, UT. Dr. Merrill is a Partner at Illinois Retina Associates and Section Director of Uveitis in the  Department of Ophthalmology  at  Rush University Medical Center .

• Syndax Highlights 2019 Clinical and Corporate Outlook

  07 January 2019

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today provided a 2019 clinical and corporate outlook.

• Healthcare Executive from Amazon Joins binx health Board of Directors

  07 January 2019

  

  binx health, a pioneer in convenient health, today announced that it has appointed Samar Parikh to its Board of Directors. Mr. Parikh has held various leadership positions within Amazon, including as an early catalyst behind its entry into healthcare. Parikh was also instrumental in the company's recent acquisition of PillPack. His roles at Amazon have included Global Leader, Business Development & Strategy (Consumables & Consumer Healthcare) and General Manager, CPG, Consumer Healthcare, and Consumer Healthcare Innovation, where he was responsible for managing Amazon's retail businesses across consumer-packaged goods, consumer healthcare and medical devices.

• Tragara Pharmaceuticals Appoints Scott Megaffin as Chief Executive Officer and Changes Name to Adastra Pharmaceuticals

  03 January 2019

  

  Tragara Pharmaceuticals Inc. today announced the appointment of Scott Megaffin as Chief Executive Officer and a member of the Board of Directors effective immediately. Megaffin brings extensive leadership experience in clinical stage companies in oncology, specialty and critical care. He replaces Tom Estok, who will remain active with the company as an advisor and continue in his role on the Board of Directors.

• Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis

  19 December 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that it has submitted a New Drug Application (“NDA”) for XIPERETM to the  U.S. Food and Drug Administration  (“FDA”) for the treatment of macular edema associated with uveitis. 

• binx health's Rapid, Point-of-Care Platform Shows Clinical Strength for Chlamydia Testing in Study by Johns Hopkins University and National Institutes of Health

  18 December 2018

  

  Patients wondering if they have the sexually transmitted infections ("STI") chlamydia or gonorrhea may soon be able to get the results in about 30 minutes, according to new research funded through the National Institutes of Health. The binx health (formerly Atlas Genetics) result could lead to immediate treatment and an associated reduction in the spread of the infection. The World Health Organization has identified chlamydia and gonorrhea, among the most prevalent STIs, as organisms without an available point-of-care (POC) test.